Analyst Price Target is $4.50
▲ +1,235.31% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for BiomX in the last 3 months. The average price target is $4.50, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 1,235.31% upside from the last price of $0.34.
Current Consensus is
The current consensus among 3 investment analysts is to buy stock in BiomX. This Buy consensus rating has held steady for over two years.
BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.